Eli Lilly increases investment for manufacturing to $9bn at new Indiana site
Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with a new $5.3bn investment, increasing its investment at this site to $9bn from its original $3.7bn.
The expansion is intended to increase the company’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injections for the treatment of more adults with chronic diseases such as obesity and type 2 diabetes.
David A Ricks, Eli Lilly’s chair and chief executive officer at Eli Lilly, commented: “Today’s announcement tops the largest manufacturing investment in our company's history and, we believe, represents the single largest investment in synthetic medicine API manufacturing in
US history. This multi-site campus will make our latest medicines, including Zepbound and Mounjaro, support pipeline growth, and leverage the latest technolog y and automation for maximum efficiency, safety and quality control. Importantly, we are investing in our home state of Indiana, creating high-wage, advanced manufacturing, engineering and science jobs for hundreds of current and future Hoosier families.”
Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, added: “Lilly’s commitment to meeting the demand for our life-changing medicines goes beyond buildings and extends to improving education opportunities and upskilling a global workforce of the future. Academia is a critical partner to both industry and government as we work together to advance innovation in our state and communities around the globe.”
Indiana Governor Eric J Holcomb, stated: “Lilly continues to play a transformational role in shaping Indiana's opportunity economy, and I couldn't be more proud about their pole position leadership in developing the LEAP Research and Innovation District in Lebanon, Indiana. Lilly has long been driving global innovation and economic growth that will be felt for decades here at home. As an international company, headquartered in Indiana, Lilly had a world of options to consider before making this investment, and choosing Indiana once again reinforces the incredible environment we've cultivated and the talented workforce we have to carry Lilly's success forward. I can't wait to see the incredible benefits this investment leads to for patients around the world, knowing they were made in Indiana.”